Complement as a target in COVID-19?

Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.

Abstract

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

MeSH terms

  • Betacoronavirus / immunology
  • Complement Activation* / drug effects
  • Complement Inactivating Agents / therapeutic use
  • Complement System Proteins / immunology*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy
  • Drug Delivery Systems
  • Humans
  • Immunotherapy
  • Pandemics
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy
  • Respiratory Distress Syndrome, Adult / immunology
  • Respiratory Distress Syndrome, Adult / therapy
  • Respiratory Distress Syndrome, Adult / virology

Substances

  • Complement Inactivating Agents
  • Complement System Proteins

Supplementary concepts

  • COVID-19
  • COVID-19 drug treatment
  • severe acute respiratory syndrome coronavirus 2